Phuturdex › Diseases › Glycogen storage disease
Drugs in development · updated 30 October 2026
Glycogen storage disease: drugs in development
As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 4 drugs for glycogen storage disease. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| S-606001 | II | 3 | NCT07750990 |
| AB-1009 | I–II | 1 | NCT07282847 |
| ATR 1072 | I–II | 1 | NCT07738107 |
| MRNA-3745 | I–II | 1 | NCT05095727 |
Sorted by most advanced phase and number of active trials.
All 4 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Glycogen storage disease II 9 drugs
- Lysosomal storage disease 11 drugs
- Hypertrophic cardiomyopathy 16 drugs
- Cardiomyopathies 23 drugs
- Left ventricular hypertrophy 4 drugs
Broader categories
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Metabolism, Inborn Errors 6 drugs
- Genetic disease 33 drugs
- Metabolic brain disease 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006008 “Glycogen Storage Disease”. Prevalence: Orphanet.